Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.

Abstract

BACKGROUND Autologous haemopoietic stem-cell transplantation (HSCT) improves survival in patients with multiple myeloma, but disease progression remains an issue. Allogeneic HSCT might reduce disease progression, but can be associated with high treatment-related mortality. Thus, we aimed to assess effectiveness of allogeneic HSCT with non-myeloablative… (More)
DOI: 10.1016/S1470-2045(11)70243-1

Topics

7 Figures and Tables

Cite this paper

@article{Krishnan2011AutologousHS, title={Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.}, author={Amrita Y. Krishnan and Marcelo C. Pasquini and Brent R Logan and Edward A. Stadtmauer and David H. Vesole and Edwin P Alyea and Joseph H Antin and Raymond L. Comenzo and Stacey Goodman and Parameswaran N. Hari and Ginna G. Laport and Muzaffar H Qazilbash and Scott Rowley and Firoozeh Sahebi and George Somlo and Dan T. Vogl and Daniel Weisdorf and Marian G Ewell and Juan Wu and Nancy L. Geller and Mary Horowitz and S. Giralt and David G Maloney}, journal={The Lancet. Oncology}, year={2011}, volume={12 13}, pages={1195-203} }